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2I. Abstract:
Breast cancer remains the second most common cause of cancer death in the United
States. Several studies have identified cohorts of women at higher than average risk to
develop this disease. These are women who are exposed to high levels of endogenous or
exogenous estrogens, those with a family history of breast cancer, and those who harbor
benign breast disease or genetic mutations that predispose to breast cancer. In this
population group, adapting a chemoprevention strategy to decrease the risk of developing
overt disease is a strong consideration. To this end, tamoxifen is the most accepted agent
to date. This article will describe high risk categories that predict future development of
invasive breast cancer, will summarize the current available data to support the use of
tamoxifen for chemoprevention, and will further discuss adverse effects of tamoxifen as
well as measures to anticipate and monitor for possible adverse outcomes.
II. Introduction:
An estimated 214,640 American women will be diagnosed with breast cancer in 2006,
according to American Cancer Society statistics (1). It is the second most common cause
of cancer death and the main cause of death for women aged 45-55. Women recognized
to be at higher risk than the average population for the development of breast cancer have
historically been identified as those associated with exposure to higher (or longer) levels
or circulating estrogens, including older age, early menarche and later menopause,
nulliparity, older age at first full-term pregnancy, and history of current or past use of
hormonal replacement therapy (containing estrogen and progesterone) (1). In addition,
women considered at high risk include those with family history of breast cancer,
personal history of previous breast biopsy(ies) or diagnosis of benign proliferative breast
3disease, personal history of radiation exposure, and those who harbor specific genetic
mutations (BRCA1, BRCA2, p53, or PTEN), Chemoprevention as a strategy to interfere
with the development of breast cancer in women with high risk scenarios is emerging as a
strong consideration for women’s health. In this regard, tamoxifen has currently been the
most widely accepted agent, patterning after well-established data from its use in the
treatment and risk-reduction of breast cancer in the adjuvant setting.
III. Tamoxifen for prevention:
Several studies have sought to identify subsets of women who would be at highest risk
for the development of breast cancer. The Gail Risk model has historically been used to
predict the 5-year as well as lifetime risk of developing invasive breast cancer. This is a
validated prediction model using five factors: current age, age at menarche, previous
breast biopsies, age at first live birth, and family history of breast cancer in first-degree
relatives (2-4). A 5-year risk of 1.66% or greater strongly promotes consideration for
prevention strategies. The Claus model is an additional tool which can provide an
estimate of future breast cancer risk in women with strong family histories of breast
cancer (5).
There are four prominent studies reported in the literature comparing tamoxifen with
placebo in the prevention of breast cancer for women considered at high risk (6). The
American Breast Cancer Prevention Trial (P-1 study) sponsored by the National Surgical
Adjuvant Breast and Bowel Project (NSABP) was a randomized trial of tamoxifen versus
placebo in women considered at increased risk defined as: age older than 60, age between
35-59 with a Gail model prediction value at least 1.66%, or age 35 or greater with history
4of lobular carcinoma in situ (LCIS). The trial was terminated early after a median follow-
up of 48 months when interim analysis established a statistically significant benefit with
tamoxifen (7). There was 49% relative risk reduction and 21% absolute risk reduction of
invasive breast cancer among the cohorts on tamoxifen. Furthermore, an update of this
study showed a 62% reduction of invasive breast cancer in the tamoxifen group but the
incidence for ER-negative tumors was unchanged (8).
The International Breast Cancer Intervention study (IBIS-I) also demonstrated substantial
risk reduction for the development of breast cancer with the use of tamoxifen. This study
conducted in the UK, Australia, New Zealand and other European countries accrued data
from April 1992 to March 2001, and included women age 35-70 years considered to be at
high risk for breast cancer on the basis of a positive family history or a personal history
of atypical hyperplasia or lobular carcinoma in situ. A total of 7,152 participants were
randomized in a double-blind fashion to either placebo or tamoxifen 20 mg per day for 5
years. With a median follow-up time of 50 months, there was a 32% reduction of risk of
breast cancer in the experimental arm. In this trial, age, degree of risk and use of
hormone-replacement therapy did not affect the reduction (9). There was a 31% reduction
of risk in ER-positive invasive tumors with tamoxifen use but no demonstrated reduction
in the risk for the development of ER-negative invasive tumors. There were no additional
data to support any further benefits from the use of tamoxifen beyond 5 years.
Two other noteworthy European trials utilizing tamoxifen for breast cancer risk reduction
have recently been reported. The Royal Marsden Hospital Trial evaluated 2471 women
between ages 30 and 70 with a positive family history for breast cancer, but found no
5significant difference between tamoxifen and placebo in the subsequent frequency of
breast cancer observed (10). The Italian Tamoxifen Prevention study evaluated 5408
women between ages 35 and 70, all of whom had undergone previous hysterectomy.
Also, those with a history of thromboembolism were excluded. Thus far, no difference in
the rate of breast cancer events was detected between tamoxifen and placebo arms at
median follow-up of 30 months (11). These European trials are smaller than the above
mentioned NSABP and International trials, and did not include women with high risk
benign lesions such as LCIS or ADH.
IV. High-Risk Benign Breast Lesions and Genetic Predisposition:
Recently, investigators have sought to define the types of benign breast disease at highest
risk for the development of breast cancer. To this end, Hartman et al followed 9,087
women diagnosed with a benign breast disease at the Mayo Clinic over 15 years between
1967 and 1991 and estimated their risks for breast cancer for the spectrum of benign
breast histopathologies identified (see Figure 1) (12). They established a relative risk of
breast cancer of 4.24 over the general population for women with atypia as compared
with normal cohorts, 1.88 relative risk with proliferative changes without atypia, and 1.27
relative risk for non-proliferative lesions (12), with significantly higher risk in younger
individuals who were diagnosed with atypia (see Figure 2). They concluded that family
history of breast cancer, defined as at least one first degree relative diagnosed with breast
cancer before age 50 or two or more relatives diagnosed with breast cancer with one
being a first-degree relative (12), portended an increased risk that was independent of the
benign histology, as even nonproliferative lesions were then associated with increased
6relative risk (see Figure 2, not statisticially significant). Importantly, they found no
additional increase in risk for women with no family history and who had
nonproliferative disease on breast biopsy (12).
Hershman et al analyzed the effectiveness of tamoxifen in the very high risk cohorts of
women ages 35, 50 and 60 with Gail Risk model estimates of greater than 5%, and with
atypical ductal hyperplasia, lobular carcinoma in situ, or having two or more first-degree
relatives with breast cancer (13). They found that the greatest benefit of the use of
tamoxifen was seen in the cohort with atypical ductal hyperplasia in whom survival
benefits were prolonged by 202, 89, and 45 days respectively, depending on age, and was
deemed a cost-effective maneuver in their care. These highlight the formal description of
high risk- breast lesions which would be well-served with risk reduction strategies.
Further historical data from the NSABP P-1 study have been used to examine the effect
of tamoxifen treatment on the incidence of benign breast disease in women at high risk
for breast cancer (14). The relative risk of breast cancer for patients with adenosis, cyst,
duct ectasia, fibrocystic disease, fibroadenoma, fibrosis, hyperplasia, or metaplasia was
estimated for participants who received either tamoxifen or placebo (14). Overall,
tamoxifen reduced the risk of the development of breast cancer from these benign breast
diseases by 28%, occurring predominantly in the subset of women younger than 50 years
(14). This further strengthens the rationale for the use of tamoxifen as a chemopreventive
strategy.
Another cohort of women at high risk for development of breast cancer are those with
BRCA mutations. Carriers of both BRCA1 and 2 have an 80% lifetime risk for breast
7cancer (15). These mutations also confer a risk of cancer in the opposite breast of
approximately 3% per year (16). However, there are limited data on the benefits of
tamoxifen in this situation to date (17,18). The P-1 trial had 19 participants with
BRCA1/2 mutations who later developed breast cancer. Use of tamoxifen reduced
disease in BRCA2 but not in BRCA1 carriers (17-19). Prophylactic surgery can certainly
afford women who harbor BRCA1/2 mutations a substantial reduction of risk of breast
cancer (20-23). For women who wish non-surgical methods of risk reduction, however,
the small sample size of patients in studies with tamoxifen as chemoprevention limits the
ability to support any conclusive evidence in this regard.
V. Guidelines for Chemoprevention
The National Comprehensive Cancer Network (NCCN) and the American Society of
Clinical Oncology (ASCO) have established guidelines to offer women with high risk
scenarios for the development of breast cancer the option of taking tamoxifen as
chemoprevention after surgical options are considered (6). This risk assessment now
includes evaluation for atypical hyperplasia or LCIS, and makes the recommendation for
risk reduction therapy counseling for those patients who have a 5-year breast cancer risk
of greater than or equal to 1.7% and a life expectancy of 10 years or greater. The
duration of five years of treatment with tamoxifen for those patients who both desire risk
reduction therapy as well as have no contraindication to tamoxifen, is extrapolated from
the NSABP Breast Cancer Prevention Trial P-1 data.
8VI. Following Patients on Tamoxifen
Physicians must also be cogniscant of the expected side effect profile of tamoxifen in
order to anticipate symptoms, follow patients, and support women who are taking
tamoxifen (24). Expected side effects include hot flashes, risk of deep venous
thrombosis, retinopathy and cataract formation. Routine follow-up should include
ophthalmologic examination for older individuals, and routine gynecologic examination
including pelvic exam with Papanicolau screening. The overall rate of uterine sarcoma in
the NSABP trials for women on tamoxifen (whether for prevention or in the adjuvant
setting) was reported as 0.17/1,000 women-years or approximately less than 1 percent.
The NCCN also highlights the need for prompt gynecologic evaluation of
postmenopausal vaginal spotting or bleeding. Premenopausal patients may also benefit
from bone mineral density screening as paradoxically, tamoxifen may induce bone loss in
premenopausal women, but increase bone density in postmenopausal women (6).
Patients should also be counseled to undergo monthly breast self-examination, and to
avoid pregnancy during tamoxifen exposure. Discontinuation of tamoxifen is
recommended on a short-term basis for patients undergoing elective surgery, and
permanently for patients who suffer deep venous thrombois, pulmonary embolism, or
stroke.
VII. Ongoing Studies
Ongoing studies evaluating other selective estrogen receptor modulators (SERMs) or
aromatase inhibitors (AIs) for chemoprevention of breast cancer in women at high risk
may provide other alternative strategies with different side effect profiles as compared
9with tamoxifen. Raloxifene, also a SERM, differs from tamoxifen in that it bind to the
estrogen receptor to block estrogen-mediated DNA transcription. Raloxifene is FDA-
approved for the treatment and prevention of osteoporosis in postmenopausal women
(25). The MORE trial (Multiples Outcomes of Raloxifene Evaluation) showed a
significant reduction in postmenopausal osteoporosis as well as breast cancer incidence in
women treated with raloxifene. In this trial, 7705 postmenopausal women with
osteoporosis were randomized to placebo, 60 mg/day or 120 mg/day raloxifene for 3
years. After a median follow-up of 40 months, women treated with raloxifene enjoyed a
significant reduction in fracture risk and an increase in bone mineral density as compared
with those treated with placebo. In addition, the use of raloxifene showed as a secondary
endpoint a reduction in the relative risk of the development of invasive breast cancer by
76% (95% CI, 0.13-0.44), with a decreased risk primarily in estrogen-receptor-positive
cancers (26, 27). Side effects due to raloxifene were reported to include hot flashes,
peripheral edema, leg cramps, and thromboembolic events [deep venous thrombosis
(0.7% vs. 0.2% in placebo) and pulmonary embolism (0.3% vs. 0.1% in placebo), but no
increase in the risk of endometrial cancers (26,27). Similarly, the CORE trial
(Continuing Outcomes Relevant to Evista) continued to evaluate the effect of 4 additional
years of raloxifene treatment on the incidence of invasive breast cancer in
postmenopausal women with osteoporosis, with the risk reduced by 55% (HR=0.41; 95%
CI, 0.21-0.71), and a reduction in the incidence of estrogen-receptor-positive breast
cancers by 66% (HR=0.34; 95%CI, 0.18-0.66) (28). Adverse events were similar to
those encountered in the MORE trial (28). These trials have stimulated the design of the
NSABP STAR trial (Study of Tamoxifen and Raloxifene) which was initiated in 1999,
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and has enrolled 20,000 postmenopausal women at high risk for the development of
breast cancer (29,30). At this writing, data from this trial is expected and is to be
presented at the 2006 American Society of Clinical Oncology meeting. Unpublished
results suggest that the numbers of invasive breast cancer events were similar with both
drugs, but the incidence of ductal carcinoma in situ was lower on tamoxifen (31).
Additionally, the development of uterine cancers, deep venous thromboses, and
pulmonary embolism were lower with raloxifene as compared with tamoxifen (31).
Trials utilizing other SERMs chemoprevention are ongoing (6). These include the
Raloxifene for Use in the Heart (RUTH) study (32) in which breast cancer risk is
assessed and the HOT study, in which low-dose tamoxifen added to HRT seeks to guage
risk reduction (33).
The use of aromatase inhibitors have thus far been demonstrated as reducing risk of
recurrence of breast cancer and reducing the risk of contralateral breast cancer in the
adjuvant setting with the superiority of anastrozole over tamoxifen borne out in the
ATAC trial (Arimidex, Tamoxifen, and the Combination), specifically in the subset of
women with hormone-receptor-positive breast cancer (34,35). The International Breast
Intervention Study-2 (IBIS-2) is currently ongoing, and seeks to evaluate breast cancer
risk reduction in 10,000 women with the use of anastrozole versus placebo (9).
VII. Conclusions:
Chemoprevention can be considered for breast cancer risk reduction in women with high
risk benign but proliferative breast lesions, with tamoxifen as the current standard of care.
More limited data suggests tamoxifen can be considered in women who harbor BRCA1/2
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mutations. Risks and side effects profile of tamoxifen treatment must be heavily weighed
on an individual bases, and risk models must be presented to the patient, along with
therapeutic plan for frequent mammograms, physical exams, and appropriate ancillary
follow-up. Future studies of the contribution of other SERMs and aromatase inhibition
in breast cancer risk reduction are awaited.
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Figure Legends:
Figure One:
Histologic Presentation of Benign Breast Disease. Panel A illustrates nonproliferative
fibrocystic with the formation of microcysts among normal architecture of the breast
tissue and associated with interlobular fibrosis. Panel B illustrates proliferative
hyperplasia without atypia as compared with a normal lobule on the left side. Panel C
also shows moderate proliferative hyperplasia without atypia, with. duct partially
distended by hyperplastic epithelium in the lumen. Panel D illustrates florid proliferative
ductal hyperplasia without atypia, with a “crowded, jumbled-appearing” epithelial
proliferation within the duct. Panel E shows atypical ductal hyperplasia characterized by
a combination of architectural complexity, partially formed secondary lumens, mild
nuclear hyperchromasia. Panel F shows atypical lobular hyperplasia with monotonous
cells filingl the lumens of partially distended. [From Hartmann et al, NEJM 2005;
353:229-37. Reproduced with permission from the New England Journal of Medicine,
MMS Reference Number: PS-2006-2368, MMS Invoice Number: RY-2006-2368.]
Figure Two:
Interaction Profiles for Risk-Factors and Benign Breast Disease, with Comparison of
the Number of Events Observed with the Number Expected. Panel A shows events
accounting for histologic disease compared with age; Panel B shows events compared
with age and family history; Panel C shows events compiled with respect to histologic
type and family history. CI denotes confidence interval, NP nonproliferative disease,
PDWA proliferative disease without atypia, and AH atypical hyperplasia. [From
Hartmann et al, NEJM 2005; 353:229-37. Reproduced with permission from the New
England Journal of Medicine, MMS Reference Number: PS-2006-2368, MMS Invoice
Number: RY-2006-2368.
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